Altimmune, Inc. (ALT) Earnings Call Transcripts
Altimmune, Inc.'s Latest Earnings Call - June 10, 2026
In the Q2 2026 earnings call, Altimmune, Inc. (ALT:US) highlighted significant progress in its pemvidutide program for the treatment of MASH, with management emphasizing the drug's unique mechanism and potential market differentiation. Revenue for the quarter was not disclosed, but management indicated that they have raised approximately $500 million over the past 18 months to support the upcoming Phase III trials, which are projected to cost around $400 million. The company maintained its focus on liver disease as a primary target, with the Phase III trial expected to commence patient enrollment in the second half of 2026 and results anticipated in 2029.
Reported metrics
| Metric | Value |
|---|---|
| Capital Raised | $500M (positive) |
| Phase III Trial Cost | $400M (null) |
| Enrollment Timeline | H2 2026 (positive) |
| Data Readout | 2029 (null) |
| Discontinuation Rate | Low (positive) |
Guidance from management
Management maintained a strong focus on the upcoming Phase III trial for pemvidutide, with patient enrollment expected to begin in the second half of 2026 and results anticipated in 2029.
What management said
Yes. So as always, you do the modeling, I think the 60 months is the estimate on that. We'll see how things progress -- and again, I think we feel good about our ability to enroll the right patients along the way to be able to get us to the outcomes portion. It's a requirement of the approval pathway, which is typical for MASH. And again, we're setting up the study to -- with that always as part of the right consider...
Yes. I think for us, we're basing it on what we know about the molecule to date. Obviously, the F4 population is an important population. We've seen over time, different products take different approaches. We'll -- we have a clear prioritization on the F2, F3 population at this point, and we'll continue to assess the opportunity as we move forward.
What analysts pressed on
Analysts expressed concerns regarding the execution of the Phase III trial, particularly in patient enrollment and the potential for delays, given the historical challenges in the MASH indication. There were also questions about the financial sustainability of funding multiple programs simultaneously.
Main topics on the call
- Phase III Trial Preparation — Management discussed the design of the Phase III trial for pemvidutide, emphasizing a primary endpoint at 52 weeks for biopsy outcomes. CEO Jerome Durso stated, "We think that's the right point in time to read out on bio...
- Financial Positioning — CFO Gregory Weaver noted that Altimmune has raised nearly $500 million to ensure financial stability for the Phase III program, stating, "We're well positioned now with that Belson suspenders with some additional optiona...
- Market Differentiation — Management highlighted pemvidutide's unique mechanism of action, combining GLP-1 and glucagon effects, which they believe will set it apart in the MASH treatment landscape. Durso remarked, "All glucagon GLP combos are no...
- Patient Enrollment Strategy — The company is prioritizing patient enrollment for the biopsy cohort in the Phase III trial, with a target to begin in the second half of 2026. Durso mentioned, "We are continuing to guide that we'll begin enrolling pati...
Read the full Altimmune, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Altimmune, Inc.
Altimmune, Inc. (ALT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 52 calls on record spanning March 27, 2020 to July 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 52 Altimmune, Inc. earnings call transcripts on record, spanning March 27, 2020 to July 28, 2026. Based on this history, Altimmune, Inc. reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ALT
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 52
- First call
- March 27, 2020
- Most recent
- July 28, 2026
- Reporting cadence
- quarterly